Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study.
Identifieur interne : 000B25 ( PubMed/Checkpoint ); précédent : 000B24; suivant : 000B26Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study.
Auteurs : Emmanuel Itti [France] ; Gabriel Villafane ; Zoulikha Malek ; Pierre Brugières ; Daniela Capacchione ; Laurent Itti ; Patrick Maison ; Pierre Cesaro ; Michel MeignanSource :
- Nuclear medicine communications [ 1473-5628 ] ; 2009.
English descriptors
- KwdEn :
- Administration, Cutaneous, Dopamine Plasma Membrane Transport Proteins (analysis), Dopamine Plasma Membrane Transport Proteins (metabolism), Dose-Response Relationship, Drug, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neostriatum (drug effects), Neostriatum (physiopathology), Nicotine (administration & dosage), Nicotine (therapeutic use), Parkinson Disease (diagnostic imaging), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Regression Analysis, Time Factors, Tomography, Emission-Computed, Single-Photon, Tropanes.
- MESH :
- chemical , administration & dosage : Nicotine.
- chemical , analysis : Dopamine Plasma Membrane Transport Proteins.
- chemical , metabolism : Dopamine Plasma Membrane Transport Proteins.
- diagnostic imaging : Parkinson Disease.
- drug effects : Neostriatum.
- drug therapy : Parkinson Disease.
- metabolism : Parkinson Disease.
- physiopathology : Neostriatum.
- chemical , therapeutic use : Nicotine.
- Administration, Cutaneous, Dose-Response Relationship, Drug, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Regression Analysis, Time Factors, Tomography, Emission-Computed, Single-Photon, Tropanes.
Abstract
Nicotine therapy might improve the course of Parkinson's disease. This observational study evaluated the performance of dopamine transporter imaging in follow-up patients under nicotine therapy.
DOI: 10.1097/MNM.0b013e32832cc204
PubMed: 19451839
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:19451839Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study.</title>
<author><name sortKey="Itti, Emmanuel" sort="Itti, Emmanuel" uniqKey="Itti E" first="Emmanuel" last="Itti">Emmanuel Itti</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Nuclear Medicine, H. Mondor Hospital, AP-HP, Paris 12 University, Créteil, France. emmanuel.itti@hmn.aphp.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Nuclear Medicine, H. Mondor Hospital, AP-HP, Paris 12 University, Créteil</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Créteil</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Villafane, Gabriel" sort="Villafane, Gabriel" uniqKey="Villafane G" first="Gabriel" last="Villafane">Gabriel Villafane</name>
</author>
<author><name sortKey="Malek, Zoulikha" sort="Malek, Zoulikha" uniqKey="Malek Z" first="Zoulikha" last="Malek">Zoulikha Malek</name>
</author>
<author><name sortKey="Brugieres, Pierre" sort="Brugieres, Pierre" uniqKey="Brugieres P" first="Pierre" last="Brugières">Pierre Brugières</name>
</author>
<author><name sortKey="Capacchione, Daniela" sort="Capacchione, Daniela" uniqKey="Capacchione D" first="Daniela" last="Capacchione">Daniela Capacchione</name>
</author>
<author><name sortKey="Itti, Laurent" sort="Itti, Laurent" uniqKey="Itti L" first="Laurent" last="Itti">Laurent Itti</name>
</author>
<author><name sortKey="Maison, Patrick" sort="Maison, Patrick" uniqKey="Maison P" first="Patrick" last="Maison">Patrick Maison</name>
</author>
<author><name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name>
</author>
<author><name sortKey="Meignan, Michel" sort="Meignan, Michel" uniqKey="Meignan M" first="Michel" last="Meignan">Michel Meignan</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19451839</idno>
<idno type="pmid">19451839</idno>
<idno type="doi">10.1097/MNM.0b013e32832cc204</idno>
<idno type="wicri:Area/PubMed/Corpus">000B82</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B82</idno>
<idno type="wicri:Area/PubMed/Curation">000B42</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B42</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000B42</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B42</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study.</title>
<author><name sortKey="Itti, Emmanuel" sort="Itti, Emmanuel" uniqKey="Itti E" first="Emmanuel" last="Itti">Emmanuel Itti</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Nuclear Medicine, H. Mondor Hospital, AP-HP, Paris 12 University, Créteil, France. emmanuel.itti@hmn.aphp.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Nuclear Medicine, H. Mondor Hospital, AP-HP, Paris 12 University, Créteil</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Créteil</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Villafane, Gabriel" sort="Villafane, Gabriel" uniqKey="Villafane G" first="Gabriel" last="Villafane">Gabriel Villafane</name>
</author>
<author><name sortKey="Malek, Zoulikha" sort="Malek, Zoulikha" uniqKey="Malek Z" first="Zoulikha" last="Malek">Zoulikha Malek</name>
</author>
<author><name sortKey="Brugieres, Pierre" sort="Brugieres, Pierre" uniqKey="Brugieres P" first="Pierre" last="Brugières">Pierre Brugières</name>
</author>
<author><name sortKey="Capacchione, Daniela" sort="Capacchione, Daniela" uniqKey="Capacchione D" first="Daniela" last="Capacchione">Daniela Capacchione</name>
</author>
<author><name sortKey="Itti, Laurent" sort="Itti, Laurent" uniqKey="Itti L" first="Laurent" last="Itti">Laurent Itti</name>
</author>
<author><name sortKey="Maison, Patrick" sort="Maison, Patrick" uniqKey="Maison P" first="Patrick" last="Maison">Patrick Maison</name>
</author>
<author><name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name>
</author>
<author><name sortKey="Meignan, Michel" sort="Meignan, Michel" uniqKey="Meignan M" first="Michel" last="Meignan">Michel Meignan</name>
</author>
</analytic>
<series><title level="j">Nuclear medicine communications</title>
<idno type="eISSN">1473-5628</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term>
<term>Dopamine Plasma Membrane Transport Proteins (analysis)</term>
<term>Dopamine Plasma Membrane Transport Proteins (metabolism)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Humans</term>
<term>Magnetic Resonance Imaging</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neostriatum (drug effects)</term>
<term>Neostriatum (physiopathology)</term>
<term>Nicotine (administration & dosage)</term>
<term>Nicotine (therapeutic use)</term>
<term>Parkinson Disease (diagnostic imaging)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Regression Analysis</term>
<term>Time Factors</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
<term>Tropanes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Nicotine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Dopamine Plasma Membrane Transport Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine Plasma Membrane Transport Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neostriatum</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Neostriatum</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Nicotine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term>
<term>Dose-Response Relationship, Drug</term>
<term>Humans</term>
<term>Magnetic Resonance Imaging</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Regression Analysis</term>
<term>Time Factors</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
<term>Tropanes</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Nicotine therapy might improve the course of Parkinson's disease. This observational study evaluated the performance of dopamine transporter imaging in follow-up patients under nicotine therapy.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19451839</PMID>
<DateCreated><Year>2009</Year>
<Month>06</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted><Year>2009</Year>
<Month>08</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>11</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5628</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>30</Volume>
<Issue>7</Issue>
<PubDate><Year>2009</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Nuclear medicine communications</Title>
<ISOAbbreviation>Nucl Med Commun</ISOAbbreviation>
</Journal>
<ArticleTitle>Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study.</ArticleTitle>
<Pagination><MedlinePgn>513-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/MNM.0b013e32832cc204</ELocationID>
<Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Nicotine therapy might improve the course of Parkinson's disease. This observational study evaluated the performance of dopamine transporter imaging in follow-up patients under nicotine therapy.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Six Hoehn and Yahr stage III patients underwent 123I-FP-CIT imaging prior to, 3 months, and 1 year after the onset of nicotine therapy. Nicotine was administered transdermally with increasing daily doses during 3 months (up to 105 mg/day) and decreased progressively. On co-registered magnetic resonance imaging, striatal regions of interest were drawn and binding potentials of 123I-FP-CIT were calculated.Changes in Unified Parkinson's Disease Rating Scale-III over time were compared with binding potentials using regression analysis.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">All patients improved motor scores at 3 months (-65 +/- 22% 'off', -89 +/- 12% 'on') and most received fewer dopaminergic drugs (-30% dosage in average). Motor improvement persisted to a lesser extent at 1 year(-39 +/- 31% 'off', -13 +/- 43% 'on'), partly because one patient stopped the treatment. Interestingly, the decrease in binding potentials (-4.0 +/- 10.5%) was slower than that expected in Parkinsonian patients (usually -10% per year) and was inversely correlated with Unified Parkinson's Disease Rating Scale-III improvement, r= 0.83 'off' and 0.91 'on'.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This observational study emphasizes a potential effect of nicotine therapy on striatal dopamine transporter density, which may be interpreted as direct pharmacological effect or deceleration of neuronal loss.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Itti</LastName>
<ForeName>Emmanuel</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Nuclear Medicine, H. Mondor Hospital, AP-HP, Paris 12 University, Créteil, France. emmanuel.itti@hmn.aphp.fr</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Villafane</LastName>
<ForeName>Gabriel</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Malek</LastName>
<ForeName>Zoulikha</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y"><LastName>Brugières</LastName>
<ForeName>Pierre</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Capacchione</LastName>
<ForeName>Daniela</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Itti</LastName>
<ForeName>Laurent</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Maison</LastName>
<ForeName>Patrick</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cesaro</LastName>
<ForeName>Pierre</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Meignan</LastName>
<ForeName>Michel</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Nucl Med Commun</MedlineTA>
<NlmUniqueID>8201017</NlmUniqueID>
<ISSNLinking>0143-3636</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014326">Tropanes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>155797-99-2</RegistryNumber>
<NameOfSubstance UI="C087552">2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>6M3C89ZY6R</RegistryNumber>
<NameOfSubstance UI="D009538">Nicotine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000279" MajorTopicYN="N">Administration, Cutaneous</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D050483" MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017072" MajorTopicYN="N">Neostriatum</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009538" MajorTopicYN="N">Nicotine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014326" MajorTopicYN="N">Tropanes</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>5</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>5</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>8</Month>
<Day>25</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19451839</ArticleId>
<ArticleId IdType="doi">10.1097/MNM.0b013e32832cc204</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Créteil</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Brugieres, Pierre" sort="Brugieres, Pierre" uniqKey="Brugieres P" first="Pierre" last="Brugières">Pierre Brugières</name>
<name sortKey="Capacchione, Daniela" sort="Capacchione, Daniela" uniqKey="Capacchione D" first="Daniela" last="Capacchione">Daniela Capacchione</name>
<name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name>
<name sortKey="Itti, Laurent" sort="Itti, Laurent" uniqKey="Itti L" first="Laurent" last="Itti">Laurent Itti</name>
<name sortKey="Maison, Patrick" sort="Maison, Patrick" uniqKey="Maison P" first="Patrick" last="Maison">Patrick Maison</name>
<name sortKey="Malek, Zoulikha" sort="Malek, Zoulikha" uniqKey="Malek Z" first="Zoulikha" last="Malek">Zoulikha Malek</name>
<name sortKey="Meignan, Michel" sort="Meignan, Michel" uniqKey="Meignan M" first="Michel" last="Meignan">Michel Meignan</name>
<name sortKey="Villafane, Gabriel" sort="Villafane, Gabriel" uniqKey="Villafane G" first="Gabriel" last="Villafane">Gabriel Villafane</name>
</noCountry>
<country name="France"><region name="Île-de-France"><name sortKey="Itti, Emmanuel" sort="Itti, Emmanuel" uniqKey="Itti E" first="Emmanuel" last="Itti">Emmanuel Itti</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B25 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000B25 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:19451839 |texte= Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:19451839" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |